Abstract

The high molecular weight (HMW) fibroblast growth factor (FGF)-2 isoform of 210 amino acids initiated at a CUG start codon possesses a nuclear localization sequence and is not secreted. In contrast, the low molecular weight (LMW) isoform of 155 amino acids initiated at the AUG start codon can be secreted and activates the cell surface FGF receptors. The two isoforms possess different biological properties; however, little is known about the intracrine regulatory mechanisms involved in the biological effects of the HMW FGF-2 isoform. Using pancreatic cells stably transfected with cDNAs leading to the expression of either the HMW FGF-2 (A3 cells) or the LMW form (A5 cells), we provide evidence that the two FGF-2 isoforms differentially modulate PKC levels. The LMW FGF-2 up-regulated the PKC epsilon levels by 1.6-fold; by contrast the HMW isoform down-regulated the level of this PKC isotype by about 3-fold and increased the amount of PKC delta by 1.7-fold. PKC mRNAs were also modified, suggesting that PKC expression was regulated at a pretranslational level. Additionally, expression of different levels of the HMW FGF-2 with an inducible expression system confirmed the role of this isoform on PKC delta and epsilon expressions. Increased activation of ERK-1 and -2 was also observed in cells expressing the HMW FGF-2. By using different PKC inhibitors and a dominant negative PKC delta, it was found that ERK activation was PKC delta-dependent. These data indicate that expression of HMW FGF-2 can modify PKC levels by acting at the intracellular level and that the overexpression of PKC delta induces ERK-1/2 activation. The expression of a dominant negative FGFR1 did not reduce ERK-1/2 activation by the HMW FGF-2, suggesting that ERK activation does not require FGFR activity. The signaling cascade downstream of ERK might be involved in the known mitogenic effect exerted by this FGF-2 isoform.

Highlights

  • § These authors contributed to this work. ¶ Supported by a long term fellowship from the Ligue Contre le Cancer des Hautes Alpes. ʈ Supported by a long term fellowship from the Ligue Contre le Cancer du Tarn and the Fondation pour la Recherche Medicale. ‡‡ To whom correspondence should be addressed: INSERM U 531, ILB, CHU Rangueil Bat L3 31054 Toulouse Cedex, France

  • Using pancreatic cells stably transfected with cDNAs leading to the expression of either the high molecular weight (HMW) fibroblast growth factor (FGF)-2 (A3 cells) or the low molecular weight (LMW) form (A5 cells), we provide evidence that the two FGF-2 isoforms differentially modulate PKC levels

  • Neutralizing anti-FGF-2 antibodies recognizing the common sequence of all FGF-2 forms [10, 21], suramin [18], a well established inhibitor of FGF-2 binding to FGF receptors [22], and expression of high level of dominant negative FGFR [10] inhibit the biological effects of the extracellular FGF-2, but they do not modify those evoked by the HMW FGF-2

Read more

Summary

Introduction

§ These authors contributed to this work. ¶ Supported by a long term fellowship from the Ligue Contre le Cancer des Hautes Alpes. ʈ Supported by a long term fellowship from the Ligue Contre le Cancer du Tarn and the Fondation pour la Recherche Medicale. ‡‡ To whom correspondence should be addressed: INSERM U 531, ILB, CHU Rangueil Bat L3 31054 Toulouse Cedex, France. The results obtained by confocal analysis [8] that are against a significant release of the HMW FGF-2 as well as the opposite effects of HMW and LMW FGF-2 on PKC ␦ and ⑀ expressions do not support the involvement of FGFR activation in the effects of the HMW form as reported for other cell lines [1].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call